A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
HTL will build, validate and operate a botulinum manufacturing facility in the US
The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL
The segment delivered strong sales growth of 20% YoY
The notification implies that any export of Rapid Antigen Kit will require a licence or permission from DGFT
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
The govt has rolled out three schemes for promoting the manufacture of API
Robust demand for the product across the Middle East, Africa and Latin America
Turnover of API division of ISLL stood at Rs 856.58 crore
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
Subscribe To Our Newsletter & Stay Updated
